SCHEMBL7192054

SCHEMBL7192054

COc1ccc(/C=C/C(=O)c2ccc(N)cc2)c(OC)c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 1/20 0.84
MAPT P10636 7/20 0.76
LMNA P02545 3/20 0.76
CTSL P07711 2/20 0.76
CTSB P07858 2/20 0.76
HPGD P15428 1/20 0.76
ALDH1A1 P00352 3/20 0.76
NPC1 O15118 3/20 0.76
RAB9A P51151 3/20 0.76
SMN1; SMN2 Q16637 3/20 0.76
CYP1A1 P04798 1/20 0.71
CYP1B1 Q16678 1/20 0.71
ABCG2 Q9UNQ0 2/20 0.68
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
RELA Q04206 2/20 0.65
PTPN1 P18031 1/20 0.64
KDM4E B2RXH2 2/20 0.63
MAOB P27338 1/20 0.63
TDP1 Q9NUW8 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7100049 1.00 TNFRSF1A (0.84) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL30383266 0.92 TNFRSF1A (1.00) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL30674925 0.92 TNFRSF1A (1.00) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL3215700 0.92 TNFRSF1A (1.00) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL3215707 0.92 TNFRSF1A (1.00) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL7099538 0.89 ABCG2 (0.86) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL20565018 0.89 ABCG2 (0.86) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL29394843 0.89 ABCG2 (0.86) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL7180313 0.88 TNFRSF1A (0.86) TNFRSF1AMAPTLMNACTSLCTSB
SCHEMBL29600833 0.88 TNFRSF1A (0.86) TNFRSF1AMAPTLMNACTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12447137-B2 Composition for prevention, amelioration, or treatment of cancer EWHA University—Industry Collaboration Foundation (KR) 2025-10-21 US disclosed
CN-114051408-B Composition for preventing, ameliorating, or treating cancer 梨花女子大学校产学协力团 2025-02-07 CN disclosed
US-20220226263-A1 Composition for Prevention, Amelioration, or Treatment of Cancer CHA UNIVERSITY INDUSTRY-ACADEMIC COOOPERATION FOUNDATION (KR) 2022-07-21 US disclosed
EP-3977988-A1 COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF CANCER Ewha University-Industry Collaboration Foundation (KR) 2022-04-06 EP disclosed
CN-114051408-A Composition for preventing, ameliorating, or treating cancer 梨花女子大学校产学协力团 2022-02-15 CN disclosed
WO-2020242201-A1 COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF CANCER 이화여자대학교 산학협력단 2020-12-03 WO disclosed
US-20200190024-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2020-06-18 US disclosed
CN-102397269-A Application of chalcone compounds in preparations of inflammation resisting medicines WENZHOU MEDICAL COLLEGE 2012-04-04 CN disclosed
US-6603046-B1 The invention is drawn to novel bis-aromatic a, beta -unsaturated ketones. The compounds are useful in the treatment and prophylaxis of diseases caused by parasites or bacteria. LICA PHARMACEUTICALS A/S (DK) 2003-08-05 US disclosed
EP-0634927-B1 TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA LICA PHARMACEUTICALS AS (DK) 2001-07-04 EP disclosed
US-5985935-A PARASITICIDES OR BACTERICIDES STATENS SERUMINSTITUT (DK) 1999-11-16 US disclosed
EP-0634927-A1 TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA STATENS SERUMINSTITUT (DK) 1995-01-25 EP disclosed
WO-1993017671-A1 TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA STATENS SERUMINSTITUT (DK) 1993-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190024-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT PRKAA1, PRKAA2, PRKAG1 TNFRSF1A 3803/4885MAPT 46/4885LMNA 1969/4885
US-20220226263-A1 Composition for Prevention, Amelioration, or Treatment of Cancer FABP2, FABP1, TSG101 TNFRSF1A 3114/4885MAPT 3261/4885LMNA 1370/4885
US-12447137-B2 Composition for prevention, amelioration, or treatment of cancer GSTO1, FABP1, GSTK1 TNFRSF1A 3820/4885MAPT 4437/4885LMNA 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.